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Abstract  
Significant efforts have been made in the fight against malaria in the greater 
Mekong subregion, but two-thirds of the population in Myanmar still reside in high-risk 
regions for malaria infections. Substandard and falsified antimalarial medications pose a 
threat to disease transmission, efforts to control antimalarial resistance, and eliminate 
malaria from the region. This study is the first to estimate the health and economic impact 
of substandard and falsified antimalarials in Myanmar. Malaria illness, care seeking and 
health outcomes were simulated using the Substandard and Falsified Antimalarial 
Research Impact (SAFARI) model, a probabilistic agent-based model. Myanmar-specific 
epidemiologic, demographic and cost inputs were extracted from existing literature. The 
total annual cost of malaria in Myanmar was estimated to be $14.084 (95% CI: $14.040-
14.128) million, including $2.719 (95% CI: $2.715-2.722) million in direct costs. 
Substandard and falsified antimalarials contributed $2 million to the total annual, 
including $16,000 in direct costs. The model estimated that poor-quality antimalarials 
contributed to 33% of hospitalizations in Myanmar. In the event of widespread 
artemisinin resistance, we simulated an additional $550,000 in yearly costs. The presence 
of poor-quality antimalarials are hampering efforts to reduce malarial disease burden, 
control the spread of antimalarial resistance, and eliminate malaria in Myanmar and the 
greater Mekong subregion. 
  
Introduction 
Malaria is a preventable, infectious disease transmitted by mosquito-borne parasites. 
Most uncomplicated malarial cases treated with quality, first-line antimalarials in outpatient 
settings result in full recovery. However, inadequately treated symptomatic disease can quickly 
progress to complications such as anemia or neurologic sequelae, or result in death (World 
Health Organization, 2014b). In 2017, there were an estimated 435,000 deaths worldwide due to 
malaria (World Health Organization, 2018). While significant global efforts aimed at malaria 
over the last two decades have led to substantial decreases in malaria morbidity and mortality, 
the burden largely remains in poor countries (United Nations, 2015). In Southeast Asia, malaria 
incidence rates have decreased by more than 40% between 2010 and 2017, where many 
countries in the great Mekong subregion are working towards the goal to complete elimination 
by 2030 (World Health Organization, 2015a, 2015b, 2016, 2017, 2018). However, countries such 
as Myanmar still have two-thirds of its population residing in high risk regions for malaria 
infection.  
 
One of the key challenges to malaria elimination in Southeast Asia is the emergence of 
malaria parasites that are resistant to effective medicines (World Health Organization, 2016, 
2018). Resistance to artemisinin treatment was first reported in Cambodia in 2008, and has since 
been accompanied by resistance to artemisinin partner drugs, leading to higher failure rates of 
the most effective malaria drugs, artemisinin-based combination therapies (ACTs). Resistance to 
ACTs has now been detected in five countries in the greater Mekong subregion (Imwong, Hien, 
Thuy-Nhien, Dondorp, & White, 2017). Myanmar faces the largest malaria disease burden 
within the subregion and has confirmed cases of P. falciparum  resistance to ACTs 
(World Health Organization, 2015b, 2016, 2018). 
 
Substandard and falsified antimalarials are ineffective or harmful and may be 
contributing to the emergence of resistance to artemisinin and ACTs (Nayyar, Breman, 
Newton, & Herrington, 2012; Ozawa et al., 2018; World Health Organization, 2017). The 
World Health Organization (WHO) defines substandard medications as products which 
fail to meet quality standards or lack sufficient Active Pharmaceutical Ingredient (API), 
and falsified medicines as products which “deliberately misrepresent their identity, 
composition, or source” (World Health Organization, 2017). Poor-quality antimalarials 
prolong illness, offer inadequate treatments, and increases the risk of adverse events and 
antimalarial resistance (Nayyar, et al., 2012; Ozawa, et al., 2018; World Health 
Organization, 2017). In Myanmar, studies have demonstrated that 0.0-39.2% of 
antimalarial drugs are substandard or falsified (Dondorp et al., 2004; Guo et al., 2017; 
Hajjou et al., 2015; Khin et al., 2016; P. Newton et al., 2001; P. N. Newton et al., 2008; 
Wondemagegnehu, 1999; Yong et al., 2015). 
 
While poor-quality antimalarials may pose a significant threat towards national 
and international plans to control and eliminate malaria in Myanmar and Southeast Asia, 
their impact has not been estimated to date. The impact of substandard and falsified 
antimalarials have only been presented in Africa, where a sizable burden have been 
estimated (Beargie et al., 2019; Ozawa, Evans, Higgins, Laing, & Awor, 2019; Ozawa et 
al., 2019). Given the confirmed existence of parasite resistance, we sought to understand 
the impact of poor-quality antimalarials in Myanmar to inform efforts to reach the 2030 malaria 
elimination targets. 
 
Materials and Methods 
We developed and applied the Substandard and Falsified Antimalarial Research Impact 
(SAFARI) model to examine the impact of poor-quality antimalarials in Myanmar. This model 
simulates malaria infection, patient care-seeking, disease progression, treatment outcomes, and 
associated costs. A detailed description of the model can be found in other publications (Beargie, 
et al., 2019; Ozawa, Evans, et al., 2019; Ozawa, Haynie, et al., 2019) and modifications specific 
to Myanmar are described here (Ozawa, Evans, et al., 2019). We first conducted a literature 
search for malaria and Myanmar to identify and utilize relevant accessible data. All model inputs 
are listed in Table 1. Key data sources we used included the vector borne disease control 
program (VBDC) report from the Myanmar Ministry of Health, WHO world malaria report, the 
ACTwatch outlet report, and the Demographic and Health Survey (DHS) for Myanmar, in 
addition to published literature. Key data inputs were simulated to vary probabilistically to 
account for natural variations in epidemiological and cost inputs. Epidemiological data were 
varied based on beta distributions and cost data were ranged using gamma distributions.  
 
 The model simulates 1,000 individuals of all ages with malaria due to P. falciparum and 
P. vivax parasites in a five-day period, accumulated over one-year. We then ran this model 
10,000 times. Each modeled case of malaria represented around 24 real world cases in Myanmar. 
At the beginning of each five-day period, individuals with symptomatic malaria infection 
decided whether and where to seek care resulting in variations on medication use and disease 
outcomes. At the end of the week, patients either became healthy, asymptomatic, died, or 
remained sick. Outcomes were tracked throughout the model year and averaged at the 
model. Sensitivity analysis to validate this method was conducted by increasing the ratio 
of modeled cases to actual cases and comparing the outputs to ensure no significant 
difference.  
 
We modeled seven options for people to seek treatment for malaria: they could go 
to 1) public facilities, 2) private facilities, 3) pharmacies, 4) informal private sector (drug 
shops or itinerant drug vendors), 5) community health workers (CHWs), 6) self-treat, or 
7) not seek care. Available stock of medications at each location based on national data of 
antimalarial market share determined the probability that patients received different types 
of treatment, such as ACTs, artemisinin monotherapy, chloroquine, primaquine, and 
others (e.g. sulfadoxine–pyrimethamine) (ACTwatch Group and Population Services 
International Myanmar, 2016). Current national treatment guidelines for uncomplicated 
cases of P. falciparum malaria in Myanmar include three ACTs: artemether lumefantrine 
(AL), dihydroartemisinin piperaquine (DHA-PPQ), or artesunate mefloquine (AS-MQ) 
(World Health Organization, 2015b). First-line treatment for radical cure of P. vivax 
malaria is chloroquine to treat blood stage parasites, accompanied by primaquine to treat 
latent liver stage parasites that can cause relapses (World Health Organization, 2015b). 
Some individuals received no treatment due to a stock out based on data on frequency of 
stock outs of ACTs (ACTwatch Group and Population Services International Myanmar, 2016). 
Individuals who did not seek care or received no drug at a facility remained symptomatic into the 
next five-day period where they again had the chance to decide whether to seek care. Individual 
treatment outcomes were determined based on the efficacy of the medicine they received, 
adjusted by medication quality (amount of API) and patients’ modeled adherence. Adherence 
rates were obtained from a study assessing adherence to six-dose regimen of artemether-
lumefantrine in Myanmar (Z. W. Tun et al., 2012). 
Treatment efficacy was defined as medication-specific likelihood of adequate clinical and 
parasitological response at 28 days based on polymerase chain reaction (PCR) (Chu et al., 2018; 
Ejov, Tun, Aung, & Sein, 1999; Htun et al., 2017; Muhamad, Ruengweerayut, Chacharoenkul, 
Rungsihirunrat, & Na-Bangchang, 2011; Myint et al., 2017; Na-Bangchang, Ruengweerayut, 
Mahamad, Reungweerayut, & Chaijaroenkul, 2010; Nyunt et al., 2017; Phyo et al., 2011; Shwe, 
Lwin, & Aung, 1998; Frank Smithuis et al., 2006; Frank  Smithuis et al., 2004; F. M. Smithuis et 
al., 2010; K. M. Tun et al., 2018; Yuan et al., 2015; Zwang et al., 2009). We incorporated 
substandard and falsified antimalarials based on prevalence by medicine from the literature, 
where poor quality antimalarials were assigned lower API concentrations found from studies 
testing antimalarials (Tabernero et al., 2015). 
 
We used data from the VBDC report on the number of cases of severe malaria and 
malaria related hospitalizations to estimate probabilities that treated cases would progress to 
become severe (Department of Public Health, 2015). For untreated cases of malaria, we 
employed rates of progression to severe disease reported by a Delphi study (Lubell et al., 2011). 
Agents that sought care with severe malaria became hospitalized and received inpatient care. 
Severe malaria patients faced the probability of dying, resulting in neurologic sequelae, or fully 
recovering to become healthy.  Rates of progression to neurologic sequalae or death were 
obtained from a study in Southeast Asia (Southeast Asian Quinine Artesunate Malaria Trial 
(SEAQUAMAT) Group, 2005). Modeled results were scaled to the population of 
Myanmar based on the number of new cases simulated to estimate the annual malaria 
burden in the country.  
  
Primary model outputs were estimates of health outcomes, direct costs and 
productivity losses. Direct costs included costs to patients such as transportation, testing, 
medication, consultation, and hospitalization costs, and costs to public facilities and 
CHWs for providing treatment (ACTwatch Group and Population Services International 
Myanmar, 2016; Naing and Gatton, 2004; World Health Organization, 2010). Indirect 
costs included productivity losses for care-seeking, disability, or premature death. 
Productivity losses were estimated using the human capital approach where lost earnings 
were calculated based on gross domestic product (GDP) per capita and duration of 
productivity losses (The World Bank, 2019). Care seeking productivity loss was 
estimated to be between three to five days of lost earnings, while lifetime productivity 
losses were calculated from the average age of death due to malaria until average life 
expectancy, discounted at 3% (Chen, Aung, Thant, Sudhinaraset, & Kahn, 2015). 
Disability productivity losses were estimated by applying the disability weights for 
neurologic sequelae to discounted lifetime productivity losses. All cost outputs were 
rounded to the nearest thousands and expressed in 2017 United States Dollars (USD).  
 
We ran the simulation across three scenarios. The baseline scenario simulates the 
overall burden of malaria in Myanmar at current levels of antimalarial quality. A second 
scenario simulating no substandard and falsified antimalarials was compared to the 
baseline to elucidate the health and economic impact of poor-quality antimalarials. Finally, a 
third scenario simulated hypothetical widespread ACT resistance in which the cure rate of ACTs 
was reduced to that of other antimalarials, and patients receiving ACTs experienced five more 
days of prolonged illness (Dondorp, et al., 2004; Khin, et al., 2016; Yong, et al., 2015). These 
scenarios were compared to baseline using unpaired two-sample t-tests.  
 
Results 
  Table 2 presents the annual health and economic burden of malaria in Myanmar. Based 
on around 117,000 (95% CI: 116,982-117,018) cases of malaria per year, we estimated that 
malaria results in 899 (95% CI: 895-903) severe cases, 449 (95% CI: 447-452) hospitalizations, 
and 202 (95% CI: 201-203) deaths annually. Costs of care seeking and productivity losses added 
up to $14.084 (95% CI: $14.040-14.128) million annually, which consisted of $2.719 (95% CI: 
$2.715-2.722) million in direct costs and $11.365 (95% CI: $11.321-11.409) million in 
productivity losses. Direct costs included $2.2 million in care, $71,000 in medications, and 
$1,400 in testing. Productivity losses for care-seeking totaled $5.093 (95% CI: $5.086-5.099) 
million and lifetime productivity losses from disability or early death was estimated at $6.272 
(95% CI: $6.229-6.316) million.  
 
Substandard and falsified antimalarials contributed to 15 (3%) hospitalizations (p < 
0.001) and 67 (33%) deaths (p < 0.001) annually. Moreover, substandard and falsified 
antimalarials accounted for 15% of the current economic impact of malaria in Myanmar 
estimated at $2.04 million (p < 0.001). The impact of poor-quality antimalarials consisted mainly 
of lifetime productivity losses accrued from premature death and disability. Direct costs were 
estimated at around $16,000 annually (p < 0.001), including out-of-pocket costs to the 
patient and public facility costs for public facilities.   
 
Our hypothetical scenario of antimalarial resistance reduced the effectiveness of 
ACTs and increased the duration of illness. This scenario resulted in a 3.6% increase in 
severe cases where 32 more malaria cases became severe each year (p < 0.001),  leading 
to 16 (3.5%) more deaths annually (p < 0.001). The antimalarial resistance scenario 
increased the total economic burden of malaria $550,000 (p < 0.001). This additional cost 
due to antimalarial resistance consists of approximately $104,000 in direct costs and 
$442,000 in productivity losses. 
 
Discussion 
Our results demonstrate the need for Myanmar to ensure antimalarial quality in 
order to reduce the burden of malaria and reach 2030 malaria elimination targets. Based 
on the best available data, we estimated that substandard and falsified antimalarials 
currently contribute to 37% of the deaths each year with an impact of over $2 million 
annually, equivalent to around 2.9% of Myanmar’s GDP (The World Bank). This is 
substantial as the country’s total expenditure on health was 2.3% of GDP in 2014 in 
comparison (World Health Organization, 2014a). The burden of malaria could increase 
even further if the prevalence of poor-quality antimalarials continues and resistance to 
ACTs increase.   
Poor-quality antimalarials directly hinder priorities outlined by Myanmar’s 
National Plan for Malarial Elimination such as “interrupting transmission of and 
eliminating P. falciparum malaria with special emphasis on areas of multi-drug and artemisinin 
resistance.” Utilizing high-quality medicines leads to shorter and less severe illness, lending to 
fewer fatalities and less opportunity for spread of contagious diseases and accumulation of drug 
resistance (Bassat, Tanner, Guerin, Stricker, & Hamed, 2016). Antimalarial resistance and 
inability to achieve malarial elimination in Myanmar harm neighboring countries in the Greater 
Mekong Subregion (GMS) and risk the spread of resistance worldwide where the burden of 
malaria is even greater.  
 
Our results are comparable to other estimates of modeled artemisinin resistance in the 
region. For example, Lubell et al. modeled artemisinin resistance in Cambodia in 2014 by 
assuming the efficacy of artemisinin would be reduced to 70%, resulting in a 28% increase in 
direct medical costs.(Lubell et al., 2014) In our model, a reduced efficacy of ACTs to 66% 
resulted in an increase of 4.3% in direct medical costs. Lower costs of care in Myanmar and 
difference in model structures explain these differences, where Lubell et al. used a simple 
decision tree as compared to our dynamic agent-based model, which incorporated variations in 
care-seeking and costs. 
 
Compared to our model results from Africa, where we focused on the burden of malaria 
among children under age five, this analysis in Myanmar estimated the impact of malaria across 
all-ages. The malaria burden in Africa is vastly larger, with estimated cases of 200 million 
children in sub-Saharan Africa, where malaria tends to be more severe among children (World 
Health Organization, 2018). This analysis simulated 117,000 all-age cases in Myanmar given the 
target toward malaria elimination regardless of age.  
Moreover, unique characteristics of disease epidemiology in the greater Mekong 
subregion makes it important to ensure treatment quality. The biting pattern of mosquitos 
in Myanmar, which mainly bite in the early evening before children go to bed, makes 
insecticide treated nets less effective in preventing malaria (F. M. Smithuis et al., 2013a; 
F. M. Smithuis et al., 2013b). Thus for Myanmar, the most effective tool against the 
further spread of malaria is early detection and proper use of effective antimalarials. 
 
Unlike sub-Saharan Africa where malaria cases are mainly caused by the P. 
falciparum parasite, more than 30% of the malarial cases in Southeast Asia are caused by 
P. vivax parasites (World Health Organization, 2016, 2018). This epidemiological 
difference poses a unique challenge to elimination in the GMS, as P. vivax infections face 
higher rates of relapse. The life cycle of P. vivax parasites include dormant stages in liver 
cells which cause asymptomatic infection (World Health Organization, 2015b). This 
affects treatment effectiveness, where current recommended treatment is to include 
primaquine with chloroquine to prevent recrudescence. However, primaquine should not 
be given to people with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to 
the risk of red blood cell breakdown. G6PD deficiency is not easy to detect in low-
resourced settings in Myanmar.  While ACTwatch data demonstrated a need for 
increasing primaquine availability in rural Myanmar, primaquine would be ineffective in 
instances where 27% of chloroquine may be substandard and falsified (Khin, et al., 2016; 
Wondemagegnehu, 1999). 
 
The main limitation of this study is the availability of quality data for model inputs. We 
conducted a literature review to utilize the most recent literature across inputs, but some data 
were older or had to be extrapolated across the region. Furthermore, current literature 
surrounding malarial treatment in Myanmar most commonly focused on migrant populations of 
Myanmar residents who are treated in bordering countries such as Thailand, which may not be 
reflective of the broader population. We chose conservative estimates in cases of conflicting or 
outdated information. Due to limited data availability, inputs for treatment efficacy, adherence, 
and utilization may not reflect the heterogeneity of practice amongst the urban/rural or high/low 
malaria transmission regions of Myanmar. Literature regarding availability of medicines in the 
public sector were unavailable. To address these data limitations, we varied our inputs 
probabilistically over 10,000 model runs to capture the uncertainty in model estimates. 
 
Mitigating the impact of substandard and falsified antimalarials is important to lessen the 
current health and economic burden of malaria in Myanmar and meet future malaria elimination 
targets. Poor quality medicines not only prolong disease and lead to more severe cases, but also 
allow malaria to spread further, contributing to the burden of illness and facilitating the growth 
of antimalarial resistance. To make malaria elimination in Southeast Asia a reality, better 
surveillance and elimination of poor-quality antimalarials must be a greater priority.  
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Table 1. Key Model Inputs, Sources, and Assumptions  
 









Number of estimated cases 116772 182616 World Malaria 
Report 2018  
Proportion of cases that are Pf 0.68  WHO Fact Sheet 
2010 
Proportion of cases that are Pv 0.31  WHO Fact Sheet 
2010 
Proportion of malarial cases that 
were severe  
0.0036 0.00044 Calculated from: 
VBDC 2015  
Average age of death from malaria 25  Chen 2015  
Life Expectancy  67  World Bank 2019   
Healthcare-seeking   
DHS, assumed for all 
ages is same for 
children <5 
Public Facilities 0.334  
Private Facilities 0.139  
Pharmacy 0.027  
Drugstore 0.074  
CHW 0.028  
Self/ Neighbors 0.261  
No Treatment 0.136  
Probability of testing   
ACTwatch 2015 
Public Facilities 0.035  
Private Facilities 0.025  
Pharmacy 0.03  
Drugstore 0.044  





Public facilities   
ACTwatch 2015 
ACT 0.708  
Chloroquine 0.223  
Monotherapy 0.038  
Other 0.031  




Private facilities   
ACTwatch 2015 
ACT 0.6  
Chloroquine 0.165  
Monotherapy 0.133  
Other 0.102  




Pharmacy   
ACTwatch 2015 
ACT 0.401  
Chloroquine 0.283  
Monotherapy 0.2  
Other 0.116  




Drugstore   
ACTwatch 2015 
ACT 0.392  
Chloroquine 0.290  
Monotherapy 0.247  
Other 0.071  




CHW   
ACTwatch 2015 
ACT 0.708  
Chloroquine 0.223  
Monotherapy 0.038  
Other 0.031  




Self/ neighbors   
Assumption, same as 
Drugstore 
ACT 0.392  
Chloroquine 0.290  
Monotherapy 0.247  
Other 0.071  










ACTwatch 2015 Public Facilities 0.83  
Private Facilities 0.76  
Pharmacy 0.49  
Drugstore 0.312  
CHW 0.831  









ACT 0.12  
Chloroquine 0.27  
Monotherapy 0.18  
Other 0.24  
Primaquine  0  
Medication 
effectiveness 









Smithuis 2010, Tun 
2018, Zwang 2009  
Chloroquine 0.9392  Nyunt 2017, Chu 
2018, Ejov 1999, 
Htun 2017, 
Muhamad 2011, 
Phyo 2011, Yuan 
2015  
Primaquine with ACT or 
Chloroquine 
0.9770  Smithuis 2010, Chu 
2018, Muhamad 
2011, Yuan 2015 
Oral Artemisinin 
Monotherapy 
0.8099  Chu 2018, Shwe 
1998 
Other 0.6552  Smithuis 2004, Ejov 
1999  
No Treatment 0  Assumption 
Medication 
costs by facility 
Public facilities   
ACTwatch 2015 
ACT --  
Chloroquine --  
Primaquine --  
Monotherapy --  
Other --  
Private facilities   
ACTwatch 2015 
ACT $0.18 $0.02 
Chloroquine $0.10 $0.01 
Primaquine $0.04 $0.01 
Monotherapy $2.22 $0.52 
Other $0.48 $0.05 
Pharmacy   
ACTwatch 2015 
ACT $0.41 $0.04 
Chloroquine $0.17 $0.05 
Primaquine $0.30 $0.06 
Monotherapy $2.48 $0.21 
Other $0.48 $0.05 
Drugstore   
ACTwatch 2015 
ACT $0.37 $0.04 
Chloroquine $0.30 $0.03 
Primaquine $0.02 $0.04 
Monotherapy $3.18 $0.43 
Other $0.63 $0.06 
CHW   
ACTwatch 2015 
ACT --  
Chloroquine --  
Primaquine --  
Monotherapy $2.66 $0.63 
Other --  
Self/ Neighbor --  
Non-medication 
costs 
Cost per primary level 
hospitalization 
$9.60 $4.72 
WHO CHOICE 2010  
Average testing costs $0.07 $0.05 Calculated from 
testing costs and 
market share of 
testing based on 
ACTwatch 2015 
Transportation costs 19.04 Kyat  Naing 2004  
Productivity loss per sick day $3.42  Calculated from 
World Bank 2019  
(GDP per capita/365) 




 Calculated from 
World Bank 2019  
discounted at 3% 
 
ACT = Artemisinin-based combination therapy; CHW = Community health workers; GDP = Gross domestic 
product; DHS = demographic and health survey; Pf = P. falciparum; Pv = P. vivax; USD = United States Dollar; 
VBDC = Vector borne disease control; WHO CHOICE = World health organization Choosing interventions that are 




Table 2. Estimated Annual Health and Economic Impact of Substandard and Falsified Antimalarials in Myanmar 
 Burden of Malaria 
No Substandard and Falsified 
Antimalarials 
Antimalarial Resistance 

















-- -- -- -- -- -- 
Deaths 202 201 - 203 -15 -3.3% <0.001 9 6.6% <0.001 
Severe 
Cases 
899 895 - 903 -23 
-2.6% 
<0.001 32 3.6% <0.001 
Hospital-
izations 














































-17.8% <0.001 $442,000 3.9% <0.001 
 
CI = Confidence interval 
†Rounded to nearest thousands 
 
 
 
